Form 4: Teva EVP Sabag Exercises Restricted Share Units

Mark Sabag, Teva Pharmaceutical Industries' Executive Vice President, International Markets Commercial, exercised restricted share units on March 3, 2026.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial for Teva Pharmaceutical Industries Ltd., exercised Restricted Share Units (RSUs) on March 3, 2026.
• A total of 24,900 RSUs, granted on March 3, 2024, vested on March 3, 2026, and were converted into Ordinary Shares.
• An additional 141,478 RSUs, earned on January 27, 2026, due to performance criteria and vested on March 3, 2026, were also converted into Ordinary Shares.
• Following these transactions, Sabag directly beneficially owns 77,728 Ordinary Shares from the first transaction line and 219,206 Ordinary Shares from the second transaction line.
• Ordinary Shares may be represented by American Depositary Shares (ADSs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of executive equity compensation, which aligns management incentives with company performance without indicating any immediate operational changes or financial surprises.

Positives

• The exercise of RSUs indicates the vesting of previously granted equity compensation, aligning management's interests with shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
• Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Industry Context

StockSavvy.ai notes that the exercise of restricted share units is a standard component of executive compensation packages in the pharmaceutical industry, designed to incentivize long-term performance and align executive interests with shareholder value creation. This transaction reflects a routine compensation event rather than a strategic shift.

Comparison to Industry Standards

• The structure of RSU grants with performance and time-based vesting is common across major pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis, which also utilize similar equity compensation plans to retain and motivate key executives.
• The conversion of RSUs into ordinary shares at a $0 exercise price is typical for such awards, as the value is derived from the underlying share price at the time of vesting, rather than an exercise payment.

Stakeholder Impact

• Shareholders: The exercise of RSUs increases the number of outstanding shares, potentially causing minor dilution, but also signals management's continued stake in the company.
• Employees: This transaction is part of a standard executive compensation program, which can serve as a model or incentive for other employees.

Next Steps

• 24,901 restricted share units are scheduled to vest on March 3, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the exercise of restricted share units. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction aligns executive interests with shareholders but offers no fresh catalysts for a 'buy' or 'sell' decision, thus maintaining a 'hold' stance is appropriate based solely on this filing.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Restricted Share Units, RSU, Equity Compensation, Mark Sabag, Executive Compensation